miRagen Therapeutics, based in Boulder, Colo., focuses on discovery and development of microRNA-targeting therapies for diseases with high unmet need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to advance its pipeline. Its lead programs include MRG-106 (an antimiR to microRNA-155) and MRG-201 (a promiR to microRNA-29b). miRagen has a collaboration and license agreement with Servier for certain cardiovascular programs while retaining U.S. and Japan rights for those partnered programs. The company announced a Series C financing to provide capital for advancing product candidates into clinical development. Management states the proceeds will be used to advance MRG-106 and MRG-201 into clinical development this year. MiRagen Therapeutics develops microRNA-based therapeutics aimed at treating cardiovascular and muscle diseases. The company's core approach focuses on modulating microRNAs, which act as master regulators of gene expression and control sets of genes and pathways. Led by President and CEO William S. Marshall, Ph.D., MiRagen completed a $20M Series B financing to advance its programs. The company intends to use the funding to develop its miRNA-based therapeutic candidates for cardiovascular and muscle disease. The Series B was led by Remeditex Ventures with participation from Atlas Venture, Boulder Ventures, Amgen Ventures and Broadview Ventures. MiRagen is based in Boulder, CO.

Total raised

$61M

Funding rounds

2

Latest round

Series C

Latest activity

Nov 2015